bcrmut | 20821
TKI resistance BCR-ABL mutations
Keywords
BCR-ABL mutations, imatinib resistance CML, MPN, myeloproliferative neoplasms
| Material |
|
|
| Note |
There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. Since in rare cases there may also be indications of hereditary changes, the GUMG (Federal Law on Genetic Testing in Humans) provides for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent). |
|
| Min. quantity | 4 mL | |
| Stability | 1 day / 2-8°C | |
| Duration | 3 days | |
| Frequency | 2 x per week | |
| Price | CHF 0.00 | |
| Tariff | 0.00 TP | |
| Executing laboratory | External laboratory |